title: High dose rate transurethral brachytherapy as a boost dose for localized adenocarcinoma of the prostate.
abstract: From September 1989 to February 1993, 11 patients with localized adenocarcinoma of the prostate were treated with pelvic external-beam radiation therapy followed by high dose rate (HDR) transurethral brachytherapy as a boost dose. External-beam radiation therapy was administered through opposed pelvic fields using a 60Co teletherapy unit to a tumor dose of 46-50 Gy in 23-25 fractions and followed by three fractions of transurethral brachytherapy, delivered using a 60Co HDR remote afterloading equipment. The treatment time was calculated using the prostatic capsule as the reference point. The dose calculated to be delivered to the capsule was 5 Gy/fraction, making a total of 15 Gy. The follow-up period ranged from 11 to 65 months, with a median follow-up time of 30 months. Local control was achieved in all patients. The prostate-specific antigen levels were normalized within 3 months of radiotherapy in 9 patients and within 3-6 months in the remaining 2. Transurethral brachytherapy appears to be a simple and feasible form of brachytherapy. Preliminary local control and radiotherapy-related morbidity rates are comparable to those of other forms of brachytherapy. Further follow-up is required for assessment of long-term local control and delayed radiotherapy-related morbidity.
authors.affiliation: Department of Radiation Oncology, Ankara University Faculty of Medicine, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Serin
authors.forename: H S
authors.initials: HS
authors.lastname: Erkal
authors.forename: S D
authors.initials: SD
authors.lastname: Sak
authors.forename: A
authors.initials: A
authors.lastname: Cakmak
authors.forename: O
authors.initials: O
authors.lastname: Göğüş
authors.forename: A
authors.initials: A
authors.lastname: Akkaya
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000532:radiotherapy* / Q000601:surgery; D000368:Aged; D001918:Brachytherapy / Q000379:methods*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000532:radiotherapy* / Q000601:surgery; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D013997:Time Factors
chemical_list: D003037:Cobalt Radioisotopes; D017430:Prostate-Specific Antigen